Credit Suisse Ag Eiger Bio Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$0.89 - $2.52 $1 - $5	-2 Reduced 0.02%	10,500 $9,000
Q4 2022 Feb 13, 2023	SELL	$1.02 - $7.48 $239 - $1,757	-235 Reduced 2.19%	10,502 $12,000
Q3 2022 Nov 10, 2022	BUY	$6.04 - $9.66 $1,159 - $1,854	192 Added 1.82%	10,737 $81,000
Q2 2022 Aug 12, 2022	BUY	$4.99 - $8.96 $52,619 - $94,483	10,545 New	10,545 $66,000
Q1 2021 May 14, 2021	SELL	$8.44 - $12.66 $1.17 Million - $1.75 Million	-138,481 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$7.98 - $12.29 $76,041 - $117,111	9,529 Added 7.39%	138,481 $1.7 Million
Q3 2020 Nov 13, 2020	SELL	$7.96 - $12.42 $14,733 - $22,989	-1,851 Reduced 1.42%	128,952 $1.05 Million
Q2 2020 Aug 12, 2020	BUY	$5.4 - $13.37 $96,141 - $238,039	17,804 Added 15.76%	130,803 $1.26 Million
Q1 2020 May 13, 2020	BUY	$4.91 - $14.7 $90,530 - $271,038	18,438 Added 19.5%	112,999 $768,000
Q4 2019 Feb 12, 2020	SELL	$9.77 - $15.66 $400,921 - $642,623	-41,036 Reduced 30.26%	94,561 $1.41 Million
Q3 2019 Nov 12, 2019	BUY	$9.59 - $12.0 $1.3 Million - $1.63 Million	135,597 New	135,597 $1.39 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.